Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Preferred Stock Liabilities (2020)

Historic Preferred Stock Liabilities for Palisade Bio (PALI) over the last 1 years, with Q4 2020 value amounting to $9.5 million.

  • Palisade Bio's Preferred Stock Liabilities changed N/A to $9.5 million in Q4 2020 from the same period last year, while for Dec 2020 it was $9.5 million, marking a year-over-year change of. This contributed to the annual value of $9.5 million for FY2020, which is N/A changed from last year.
  • Per Palisade Bio's latest filing, its Preferred Stock Liabilities stood at $9.5 million for Q4 2020.
  • In the past 5 years, Palisade Bio's Preferred Stock Liabilities ranged from a high of $9.5 million in Q4 2020 and a low of $9.5 million during Q4 2020